Advanced Oncotherapy (FRA:R3I1) EV-to-EBITDA : -2.75 (As of Jun. 05, 2024)

Advanced Oncotherapy EV-to-EBITDA Chart

Advanced Oncotherapy Annual Data
	Trend	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21
EV-to-EBITDA		Get a 7-Day Free Trial					-3.75	-3.22	-7.60	-8.98	-10.01

Advanced Oncotherapy Semi-Annual Data
	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
EV-to-EBITDA	Get a 7-Day Free Trial															-	-8.98	-	-10.01	-

Competitive Comparison of Advanced Oncotherapy's EV-to-EBITDA

For the Medical Devices subindustry, Advanced Oncotherapy's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Oncotherapy's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Oncotherapy's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Advanced Oncotherapy's EV-to-EBITDA falls into.

Advanced Oncotherapy EV-to-EBITDA Calculation

Advanced Oncotherapy's EV-to-EBITDA for today is calculated as:

Advanced Oncotherapy's current Enterprise Value is €78.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advanced Oncotherapy's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was €-28.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Oncotherapy  (FRA:R3I1) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Advanced Oncotherapy's PE Ratio for today is calculated as:

Advanced Oncotherapy's share price for today is €0.0215.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advanced Oncotherapy's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was €-0.083.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Advanced Oncotherapy EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Oncotherapy (FRA:R3I1) Business Description